ABSTRACT
Aim
To evaluate menstrual recovery, reproductive outcomes, and survival following fertility‐sparing surgery and platinum‐based chemotherapy in women with malignant ovarian germ cell tumors (MOGCTs).
Methods
We retrospectively reviewed women aged 15–40 years with MOGCT treated at a university hospital (2001–2012). All underwent fertility‐sparing surgery and platinum‐based chemotherapy. Menstrual and reproductive outcomes were assessed through structured interviews and compared with age‐matched controls. Survival outcomes were analyzed by Kaplan–Meier method.
Results
Among 1934 ovarian cancer cases, 209 (10.8%) were MOGCT; 44 patients met inclusion criteria and were matched to 44 controls. Median age was 21 years; dysgerminoma was the most common histology (40.9%), and 70.4% had Stage I disease. All received bleomycin, etoposide, and cisplatin (median 4 cycles). After a median follow‐up of 55 months, 97.7% resumed menstruation. Compared with baseline and controls, cycles were shorter (4 vs. 5 days, p = 0.026), lighter (2 vs. 3 pads/day, p = 0.004–0.047), and longer in interval (29.2 vs. 26.4 days, p < 0.001). Of 17 patients attempting conception, 9 achieved 10 pregnancies, with a pregnancy rate of 52.9% and live‐birth rate of 90.9%, without congenital anomalies. Only one recurrence occurred, with 10‐year progression‐free and overall survival of 95.3% and 97.9%, respectively.
Conclusions
Fertility‐sparing surgery followed by platinum‐based chemotherapy was associated with excellent long‐term survival, high rates of menstrual recovery, and favorable reproductive outcomes in young women with MOGCT. These findings support current international recommendations for fertility‐preserving treatment in selected patients and provide long‐term evidence from a Southeast Asian cohort.
Keywords: germ cell, menstruation, pregnancy, surgery
1. Introduction
Malignant ovarian germ cell tumors (MOGCTs) were reported for approximately 5% of all malignant ovarian neoplasms [1]. They are derived from primordial germ cells of the ovary and include dysgerminomas and a variety of non‐dysgerminomas, such as yolk sac tumors, immature teratomas, mixed germ cell tumors, pure embryonal carcinomas, and non‐gestational choriocarcinomas. Unlike epithelial ovarian cancers, which primarily affect postmenopausal women, MOGCTs most frequently affect adolescents and young women of reproductive age [2].
Platinum‐based combination chemotherapy has transformed the prognosis of MOGCTs, achieving cure rates exceeding 80%–90% even in advanced stages [2, 3, 4]. With survival largely secured, clinical priorities now emphasize fertility preservation and long‐term quality of life, supported by evidence that most young survivors resume normal menstruation and achieve favorable pregnancy outcomes [5, 6, 7, 8, 9, 10]. Despite these promising outcomes, most published data originate from Western populations [6, 7, 8, 9, 10, 11], while evidence from Asian cohorts, particularly regarding menstrual function and fertility after chemotherapy, remains limited [11, 12]. Given potential differences in tumor biology, treatment practices, and baseline demographics, regional studies are essential. As a major tertiary referral center with extensive experience in managing MOGCT, this institution contributes evidence that complements international data and refines the characterization of reproductive outcomes in this population cohort.
The main aim of this research was to evaluate menstrual patterns in patients who underwent fertility‐sparing surgery followed by adjuvant chemotherapy for MOGCTs. The study compared these patients' menstrual function to that of age‐matched controls. Additionally, this study sought to assess fertility outcomes and survival rates among patients who survived treatment.
2. Methods
2.1. Study Design and Participants
This historical cohort study was directed at a university hospital with ethics approval. Women aged 15–40 years treated for MOGCTs between 2001 and 2012 were eligible if they had undergone fertility‐sparing surgery followed by platinum‐based chemotherapy, remained disease‐free for ≥ 6 months, had a normal menstrual history prior to treatment, and provided written informed consent. Patients with prior chemotherapy, radiotherapy, or incomplete records were excluded.
2.2. Treatment
Fertility‐sparing surgery was defined as unilateral salpingo‐oophorectomy with preservation of the uterus and contralateral ovary whenever feasible. Standard surgical staging procedures were performed, with selective lymphadenectomy. For bilateral disease, ovarian tissue was preserved through cystectomy or unilateral oophorectomy with contralateral cystectomy. All patients received three to four cycles of bleomycin, etoposide, and cisplatin (BEP) with dose adjustment for toxicity.
2.3. Data Collection
Clinical data included demographics, tumor characteristics, and treatment details. Histopathology was reviewed by a gynecologic pathologist. Menstrual and reproductive outcomes were obtained from medical records and standardized telephone interviews. Age‐matched healthy women attending outpatient clinics served as controls in a 1:1 ratio and completed the same questionnaire. Controls had no history of ovarian malignancy, chemotherapy, pelvic radiotherapy, infertility, or major gynecologic disorders known to affect menstrual function and reported regular menstrual cycles at the time of enrollment. Information on menstrual characteristics, reproductive history, and current hormonal contraceptive or hormonal therapy use was obtained during the interview. Women receiving hormonal therapy at the time of assessment were excluded from menstrual comparisons. Major clinical endpoints, including pregnancy, delivery, chemotherapy exposure, and recurrence, were validated against hospital records.
2.4. Outcomes
The primary outcomes were posttreatment ovarian function and menstrual patterns. Secondary outcomes included fertility (pregnancy rate among those attempting conception), progression‐free survival (PFS; treatment initiation to recurrence/last follow‐up), and overall survival (OS; treatment initiation to death/last follow‐up). The study was approved by the Institutional Ethics Committee (IRB No. 56‐492‐12‐3).
2.5. Statistical Analysis
Data were analyzed using R (v3.1.3). Continuous variables were reported as means or medians; categorical variables as counts and percentages. Menstrual function was compared between patients and controls using the Wilcoxon signed‐rank test. Fertility outcomes were reported as proportions. PFS and OS were estimated with Kaplan–Meier curves. Two‐sided p < 0.05 was judged significant. Missing data were assessed for each variable. Cases with incomplete key outcome data were excluded from specific analyses using complete‐case analysis. Given the small sample size and the study's retrospective nature, multiple imputation was not performed.
3. Results
Among 1934 women diagnosed with ovarian cancer during the study period, 209 (10.8%) had MOGCTs. After exclusions and inclusions, 44 patients were enrolled, along with 44 age‐matched controls (Figure 1). The median age was 21 years in both groups (patients: IQR 19–26; controls: IQR 19–23; p = 0.824). Most were single, and contraceptive use did not differ between groups (Table 1).
FIGURE 1.

Flow diagram of patient selection and enrollment.
TABLE 1.
Baseline characteristics.
| Characteristic | Patients (N = 44) | Controls (N = 44) | p |
|---|---|---|---|
| Age, years (median, IQR) | 21 (19–26) | 21 (19–23) | 0.824 |
| Marital status | |||
| Single | 27 (61.4) | 33 (75.0) | 0.550 |
| Married | 17 (38.6) | 11 (25.0) | |
| Contraception | |||
| None | 36 (81.8) | 33 (75.0) | 0.786 |
| Hormonal | 3 (6.8) | 7 (15.9) | 0.230 |
| Nonhormonal | 5 (11.4) | 4 (9.1) | 0.750 |
Note: Age presented as median (interquartile range, IQR). Other values are n (%). Comparisons were made using Wilcoxon rank‐sum test for age and chi‐squared/Fisher's exact test for categorical variables.
3.1. Tumor Characteristics and Treatment
Dysgerminoma was the most frequent histology (40.9%), followed by yolk sac tumor (27.3%), immature teratoma (18.2%), and mixed germ cell tumor (13.6%). Most patients presented with Stage IC (40.9%) or IA (29.5%) disease. Fertility‐sparing surgery consisted of unilateral salpingo‐oophorectomy in 81.8% and cystectomy in 18.2%; lymphadenectomy was performed in 22.7% (Table 2). All patients received adjuvant BEP chemotherapy (median 4 cycles, IQR 3–5). No radiotherapy was given. One patient with Stage IIIC dysgerminoma relapsed and received VAC. Median follow‐up was 55 months (IQR 40–90).
TABLE 2.
Treatment outcomes of patients with malignant ovarian germ cell tumors (N = 44).
| Characteristic | n (%) |
|---|---|
| Histopathology | |
| Dysgerminoma | 18 (40.9) |
| Yolk sac tumor | 12 (27.3) |
| Immature teratoma | 8 (18.2) |
| Mixed germ cell tumor | 6 (13.6) |
| FIGO stage | |
| IA | 13 (29.5) |
| IC | 18 (40.9) |
| IIC | 3 (6.8) |
| IIIA | 1 (2.3) |
| IIIC | 8 (18.2) |
| IV | 1 (2.3) |
| Surgical procedure | |
| Unilateral or bilateral cystectomy ± others | 8 (18.2) |
| Unilateral salpingo‐oophorectomy (SO) ± others | 36 (81.8) |
| Lymph node sampling/dissection | 10 (22.7) |
| Chemotherapy | |
| BEP | 43 (100) |
| BEP + VAC for recurrence | 1 (2.2) |
| Chemotherapy cycles, median (IQR) | 4 (3–5) |
| Follow‐up time, months, median (IQR) | 55 (40–90) |
Note: Values are presented as n (%) unless otherwise specified.
Abbreviations: BEP = bleomycin/etoposide/cisplatin; VAC = vincristine/actinomycin‐D/cyclophosphamide.
3.2. Menstrual Function
Menstruation resumed in 43 of 44 patients (97.7%). One patient underwent a subsequent hysterectomy for a benign condition. The median time to recovery was 6.5 months (95% confidence interval [CI], 4.8–10.9), with one case requiring hormonal therapy. Compared with baseline, cycles were shorter (4 vs. 5 days, p = 0.026) and lighter (2 vs. 3 pads/day, p = 0.047). Compared with controls, posttreatment patients also had shorter duration (p = 0.008), lighter flow (p = 0.004), and longer intervals (p < 0.001) (Table 3).
TABLE 3.
Comparison of menstrual patterns between patients and controls.
| Characteristic | Patients (N = 44) | Controls (N = 44) | p |
|---|---|---|---|
|
Duration, days (median, IQR) |
Pre: 5.0 (3.8–6.0) Post: 4.0 (3.8–5.0) |
6.0 (4.8–7.0) |
Pre vs. post: 0.026 a Post vs. control: 0.008 b |
|
Interval, days (mean ± SD/median, IQR) |
Pre: 26.4 ± 3.1 Post: 29.2 ± 2.1 |
26 (24–29) |
Pre vs. post: 0.144 a Post vs. control: < 0.001 b |
|
Amount, pad/day (median, IQR) |
Pre: 3 (2–3) Post: 2 (2–3) |
3 (2–5) |
Pre vs. post: 0.047 a Post vs. control: 0.004 b |
Note: Statistically significant at p < 0.05.
Wilcoxon signed‐rank test (paired within patients).
Mann–Whitney U test (patients vs. controls).
3.3. Fertility Outcomes
Among 25 sexually active patients, 17 attempted conception and nine achieved 10 pregnancies, yielding a pregnancy rate of 52.9% (95% CI, 27.8%–77.0%). Outcomes included six single live births, one miscarriage, and two subsequent successful pregnancies (four live births). In total, 10 live‐born infants were reported, resulting in a live birth rate of 90.9% (95% CI, 58.7%–99.8%), based on 10/11 pregnancies with known outcomes. No major congenital anomalies were observed.
3.4. Oncologic Outcomes
One patient with Stage IIIC dysgerminoma experienced relapse and died of progressive disease. At a median follow‐up period of 55 months (range 11–169), the 10‐year progression‐free and OS rates were 95.3% (95% CI, 84.2%–99.4%) and 97.9% (95% CI, 88.7%–99.9%), respectively (Figure 2).
FIGURE 2.

Kaplan–Meier curve of survival in 44 patients with malignant ovarian germ cell tumors. (A) Progression‐free survival. (B) Overall survival.
4. Discussion
In this historical cohort of 44 young women with MOGCTs, fertility‐sparing surgery followed by platinum‐based chemotherapy achieved excellent long‐term survival, with most patients resuming menstruation and more than half of those attempting conception achieving pregnancy. Although statistically significant changes in menstrual characteristics were observed after treatment, including shorter duration, lighter flow, and longer cycle intervals, the magnitude of these differences was relatively modest. Importantly, nearly all patients resumed regular menstruation, and reproductive outcomes remained favorable, suggesting that these menstrual changes may reflect subtle alterations in ovarian or endometrial function rather than clinically significant impairment of reproductive capacity. Therefore, while menstrual characteristics changed after treatment, these findings should be interpreted in the context of preserved menstrual recovery and successful pregnancies in the majority of women who desired conception.
In our institution, MOGCTs accounted for 10.8% of ovarian cancers, a figure notably higher than the reported global incidence of 2%–6% [13, 14, 15]. Differences across populations likely reflect genetic, environmental, and healthcare factors [16, 17]. As expected, most cases occurred in reproductive‐aged women [1, 18], highlighting the disproportionate impact of these rare tumors on fertility and survivorship [19, 20].
Our findings are consistent with large Western series, which reported that 83%–100% of MOGCT survivors resumed normal menstrual cycles and many successfully conceived [6, 7, 8, 9, 10]. Gershenson and colleagues demonstrated that most women treated with combination chemotherapy retained reproductive function [2], while Italian multicenter studies (MITO‐9) confirmed the safety of fertility‐sparing surgery [6, 9]. Similarly, Low and colleagues showed excellent reproductive recovery in Australian cohorts [1, 10]. In contrast, Asian data remain limited, with small case series suggesting similar trends [11, 12]. Our study therefore provides important evidence from a Southeast Asian population, bridging a significant knowledge gap and supporting international data.
The observed changes in menstrual characteristics, shorter duration, lighter flow, and longer cycle intervals may reflect chemotherapy‐related injury to the ovarian reserve, including cortical fibrosis and reduced follicle density [1, 3]. Cisplatin, a core component of BEP, is known to cause gonadotoxicity, although younger age at treatment is protective due to larger primordial follicle pools. The high rates of menstrual recovery and successful pregnancies observed here emphasize that subclinical menstrual alterations do not necessarily translate into impaired fertility.
Strengths of this study include histopathologic confirmation, standardized treatment, long follow‐up, and the use of age‐matched controls for direct comparison. Limitations include its retrospective design, reliance on self‐reported reproductive data, and modest sample size inherent to the rarity of MOGCT, which precluded detailed subgroup analyses. The long accrual period and historical nature of the cohort reflect the need for extended follow‐up to adequately capture reproductive outcomes, yet findings remain highly relevant given the paucity of Asian data.
Although the study period spanned from 2001 to 2012, the analysis was conducted and reported in 2025. This delay reflects the rarity of MOGCT, which required a long accrual period to obtain sufficient cases, and the necessity of extended follow‐up to evaluate long‐term ovarian function, fertility outcomes, and survival. Data collection also involved retrospective chart review, histopathologic confirmation, and structured patient interviews, all of which required substantial time for verification. Importantly, despite the historical nature of the cohort, evidence on fertility preservation in Asian women with MOGCT remains scarce, rendering these findings highly relevant to current clinical practice.
Menstrual and reproductive outcomes were assessed during scheduled clinic visits and further updated through structured telephone interviews conducted for up to 2 years after completion of therapy. The median follow‐up in this cohort was 55 months (range, 11–169), providing a sufficiently long observation window to capture late reproductive events. Nonetheless, the variability in follow‐up duration is a recognized limitation of longitudinal studies, as it introduces heterogeneity that may complicate uniform outcome comparisons across patients. At the same time, this variability reflects real‐world clinical practice, where follow‐up intervals are influenced by individual health needs, treatment responses, patient adherence, and external circumstances. This approach therefore balances methodological rigor with pragmatic feasibility, yielding data that are both clinically relevant and representative of survivorship in routine settings.
This study has several limitations. First, its retrospective design may introduce potential selection bias or information bias. Second, menstrual and reproductive outcomes were partially based on self‐reported data obtained through structured interviews, which may be subject to recall bias. Despite structured interviews and medical record verification, residual bias cannot be completely excluded. Third, the sample size was relatively small, reflecting the rarity of MOGCT, which limited statistical power and precision. However, the extended follow‐up period enhances the reliability of survival and reproductive outcomes. The relatively small cohort yields wider CI for reproductive outcomes, and the findings should therefore be interpreted with caution.
In this study, ovarian function was assessed through clinical menstrual history, a practical and accessible approach that facilitates long‐term surveillance without invasive testing [21] and enables comparison with age‐matched controls. However, menstrual history alone is less sensitive than biochemical markers and may overlook subclinical endocrine abnormalities or diminished ovarian reserve preceding overt irregularities [22]. The absence of objective measures of ovarian reserve, including serum anti‐Müllerian hormone (AMH), follicle‐stimulating hormone (FSH), estradiol levels, and ultrasonographic assessment of antral follicle count (AFC), represents an important limitation of this study. These biomarkers provide a more comprehensive evaluation of ovarian reserve and endocrine function and may identify early gonadal impairment despite preserved menstrual cyclicity. Therefore, although our findings suggest that menstrual function is largely preserved after fertility‐sparing treatment and BEP chemotherapy, they should not be interpreted as evidence of completely preserved ovarian reserve.
These findings reinforce current ESMO and NCCN guidelines, which recommend fertility‐sparing surgery in young patients with MOGCT whenever feasible [4, 5]. In resource‐limited settings, these findings provide reassurance that fertility‐sparing surgery combined with platinum‐based chemotherapy yields not only excellent survival but also meaningful fertility preservation. Future research should focus on prospective, multi‐institutional studies in Asian populations, incorporating biomarkers of ovarian reserve and long‐term quality‐of‐life outcomes, with oncofertility counseling integrated as a standard component of care.
Author Contributions
Wanapa Naphatthalung: conceptualization, data curation, writing – original draft, investigation, validation. Nungrutai Saeaib: writing – review and editing, conceptualization, investigation, validation. Aroontorn Pichatechaiyoot: conceptualization, methodology, data curation, investigation, writing – original draft. Kanet Kanjanapradit: writing – review and editing, validation. Rakchai Buhachat: conceptualization, writing – original draft, methodology, validation, writing – review and editing, supervision, formal analysis.
Ethics Statement
The study was approved by the Institutional Ethics Committee of the Faculty of Medicine, Prince of Songkla University (IRB No. 56‐492‐12‐3).
Consent
Informed consent was received from all participants.
Conflicts of Interest
The authors declare no conflicts of interest.
Acknowledgments
The authors gratefully acknowledge the support of the Faculty of Medicine, Prince of Songkla University, Thailand. We also thank the staff of the Department of Obstetrics and Gynecology and Department of Pathology for their technical assistance. This study was funded by the Faculty of Medicine, Prince of Songkla University.
Pichatechaiyoot A., Buhachat R., Naphatthalung W., Saeaib N., and Kanjanapradit K., “Menstrual Recovery and Reproductive Outcomes After Fertility‐Sparing Surgery and Adjuvant Chemotherapy for Malignant Ovarian Germ Cell Tumors: A Retrospective Cohort Study,” Journal of Obstetrics and Gynaecology Research 52, no. 9 (2026): e70462, 10.1111/jog.70462.
This work has not been presented in abstract form at any conference or scientific meeting.
Data Availability Statement
Due to institutional ethical and privacy considerations, the datasets collected during the study are not publicly available. This is primarily because they contain patient information, which is protected by patient autonomy. However, secondary data may be made available from the corresponding author upon reasonable request and with approval from the institutional review board, in accordance with the data‐sharing policies.
References
- 1. Low J. J., Ilancheran A., and Ng J. S., “Malignant Ovarian Germ‐Cell Tumours,” Best Practice & Research. Clinical Obstetrics & Gynaecology 26, no. 3 (2012): 347–355. [DOI] [PubMed] [Google Scholar]
- 2. Gershenson D. M., “Management of Ovarian Germ Cell Tumors,” Journal of Clinical Oncology 25, no. 20 (2007): 2938–2943. [DOI] [PubMed] [Google Scholar]
- 3. Williams S. D., Blessing J. A., Hatch K. D., and Homesley H. D., “Chemotherapy of Advanced Dysgerminoma: Trials of the Gynecologic Oncology Group,” Journal of Clinical Oncology 9, no. 11 (1991): 1950–1955. [DOI] [PubMed] [Google Scholar]
- 4. Colombo N., Peiretti M., Garbi A., et al., “Non‐Epithelial Ovarian Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow‐Up,” Annals of Oncology 23 (2012): vii20–vii26. [DOI] [PubMed] [Google Scholar]
- 5. National Comprehensive Cancer Network , NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 2. (NCCN, 2024). [DOI] [PubMed] [Google Scholar]
- 6. Mangili G., Sigismondi C., Lorusso D., et al., “The Role of Conservative Surgery in Malignant Ovarian Germ Cell Tumors: The MITO‐9 Study,” International Journal of Gynecological Cancer 21, no. 4 (2011): 780–785. [DOI] [PubMed] [Google Scholar]
- 7. Brewer M., Gershenson D. M., Herzog C. E., Mitchell M. F., Silva E. G., and Wharton J. T., “Outcome and Reproductive Function After Chemotherapy for Ovarian Dysgerminoma,” Journal of Clinical Oncology 17, no. 9 (1999): 2670–2675. [DOI] [PubMed] [Google Scholar]
- 8. Tangir J., Zelterman D., Ma W., and Schwartz P. E., “Reproductive Function After Conservative Surgery and Chemotherapy for Malignant Germ Cell Tumors of the Ovary,” Obstetrics and Gynecology 101, no. 2 (2003): 251–257. [DOI] [PubMed] [Google Scholar]
- 9. Mangili G., Scarfone G., Gadducci A., et al., “Is Fertility‐Sparing Surgery a Safe Option in Patients With Malignant Ovarian Germ Cell Tumors? Results From a Multicenter Italian Trial,” International Journal of Gynecological Cancer 20, no. 4 (2010): 591–596. [Google Scholar]
- 10. Low J. J., Perrin L. C., Crandon A. J., and Hacker N. F., “Conservative Surgery to Preserve Ovarian Function in Patients With Malignant Ovarian Germ Cell Tumors. A Review of 74 Cases,” Cancer 89, no. 2 (2000): 391–398. [PubMed] [Google Scholar]
- 11. Weinberg L. E., Lurain J. R., Singh D. K., and Schink J. C., “Survival and Reproductive Outcomes in Women Treated for Malignant Ovarian Germ Cell Tumors,” Gynecologic Oncology 121, no. 2 (2011): 285–289. [DOI] [PubMed] [Google Scholar]
- 12. Gershenson D. M., Miller A. M., Champion V. L., et al., “Reproductive and Sexual Function After Platinum‐Based Chemotherapy in Long‐Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study,” Journal of Clinical Oncology 25, no. 19 (2007): 2792–2797. [DOI] [PubMed] [Google Scholar]
- 13. Gershenson D. M., “Update on Malignant Ovarian Germ Cell Tumors,” Cancer 65, no. 2 (1990): 347–355. [DOI] [PubMed] [Google Scholar]
- 14. Smith H. O., Berwick M., Verschraegen C. F., et al., “Incidence and Survival Rates for Malignant Ovarian Germ Cell Tumors,” Obstetrics and Gynecology 107, no. 5 (2006): 1075–1085. [DOI] [PubMed] [Google Scholar]
- 15. Lee J. Y., Kim H. S., Jung P. S., et al., “Clinical Characteristics and Survival Outcomes of Malignant Ovarian Germ Cell Tumors: A 10‐Year Experience at a Single Institution,” International Journal of Gynecological Cancer 26, no. 1 (2016): 42–51. [Google Scholar]
- 16. Howlader N., Noone A. M., Krapcho M., et al., SEER Cancer Statistics Review, 1973–2010 (National Cancer Institute, 2013). [Google Scholar]
- 17. Koshiyama M., Matsumura N., and Konishi I., “Malignant Ovarian Germ Cell Tumors in Japan: Clinical Aspects and Management,” International Journal of Clinical Oncology 20, no. 1 (2015): 151–158. [Google Scholar]
- 18. Tangjitgamol S., Manusirivithaya S., Sheanakul C., et al., “Malignant Ovarian Germ Cell Tumors: Clinicopathological Presentation and Survival Outcomes,” Asian Pacific Journal of Cancer Prevention 11, no. 5 (2010): 1267–1272. [PubMed] [Google Scholar]
- 19. Gershenson D. M., Copeland L. J., Kavanagh J. J., Stringer C. A., Saul P. B., and Wharton J. T., “Fertility‐Sparing Surgery for Malignant Ovarian Germ Cell Tumors,” Journal of Clinical Oncology 25, no. 19 (2007): 2799–2805. [Google Scholar]
- 20. Mangili G., Sigismondi C., Lorusso D., et al., “Long‐Term Outcome and Fertility in Malignant Ovarian Germ Cell Tumors: A Multicenter, Retrospective Study of 144 Patients,” Gynecologic Oncology 152, no. 2 (2019): 266–272. [Google Scholar]
- 21. Symul L., Wac K., Hillard P., and Salathé M., “Assessment of Menstrual Health Status and Evolution Through Mobile Apps for Fertility Awareness,” NPJ Digital Medicine 2 (2019): 64, 10.1038/s41746-019-0139-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Wideman L., Montgomery M. M., Levine B. J., Beynnon B. D., and Shultz S. J., “Accuracy of Calendar‐Based Methods for Assigning Menstrual Cycle Phase in Women,” Sports Health 5, no. 2 (2012): 143–149, 10.1177/1941738112469930. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Due to institutional ethical and privacy considerations, the datasets collected during the study are not publicly available. This is primarily because they contain patient information, which is protected by patient autonomy. However, secondary data may be made available from the corresponding author upon reasonable request and with approval from the institutional review board, in accordance with the data‐sharing policies.
